DNA methyltransferase 3B acts as a co-repressor of the human polycomb protein hPc2 to repress fibroblast growth factor receptor 3 transcription

Sung-Hak Kim, Tae-You Kim(Seoul National University), Do‐Youn Oh(Seoul National University Hospital), Hwang-Phill Kim, Seock‐Ah Im(Seoul National University), Ju‐Hee Lee(Dongguk University), Jung‐Hyun Park(National Cancer Institute), Jinah Park(Seoul National University), Moon-Chang Choi, Yung‐Jue Bang(Seoul National University)
The International Journal of Biochemistry & Cell Biology
January 1, 2008
10.1016/j.biocel.2008.04.018
Cited by 11

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k